| Biomarker ID | 715 |
| PMID | 21894431 |
| Year | 2011 |
| Biomarker | serum amyloid A (SAA) |
| Biomarker Basis | Concentration Based (μg/dl) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated with α2M deficiency (without α2M deficiency: 54.7±44.5 Vs with α2M deficiency: 2.15±1.68) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:- Interleukin-6 signaling pathway,RAGE pathway,SIDS susceptibility pathways,LPA receptor mediated events,RANKL regulation of apoptosis and immune response |
| Experiment | PCa patients without α2M deficiency vs. PCa patients with α2M deficiency |
| Type of Biomarker | Prognostic |
| Cohort | 43 untreated adult men participated in this study, of whom 10 were healthy controls (mean age 62.8 years, range 52-70) and 33 were diagnosed with prostatic disease. Out of those with prostate cancer- Without α2M deficiency (n=23) and with α2M deficiency (n=10). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | Western blot |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IL-6 |